[{"address1": "321 Harrison Avenue", "address2": "Suite 900", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "(617) 949-2643", "website": "https://www.monterosatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 130, "companyOfficers": [{"maxAge": 1, "name": "Dr. Markus  Warmuth M.D.", "age": 52, "title": "President, CEO & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 924600, "exercisedValue": 0, "unexercisedValue": 2041632}, {"maxAge": 1, "name": "Dr. Filip  Janku M.D., Ph.D.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 713200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Champoux", "title": "Chief People & Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sharon  Townson Ph.D.", "age": 48, "title": "Chief Technology Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John C. Castle Ph.D.", "age": 51, "title": "Chief Data & Information Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Funderburk", "title": "Senior VP and Head of IR & Strategic Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philip  Nickson J.D., Ph.D.", "age": 44, "title": "General Counsel", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Magnus  Walter DPHIL", "title": "Senior Vice President of Drug Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Dunn", "age": 57, "title": "Vice President & Corporate Controller", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.95, "open": 4.92, "dayLow": 4.17, "dayHigh": 4.9999, "regularMarketPreviousClose": 4.95, "regularMarketOpen": 4.92, "regularMarketDayLow": 4.17, "regularMarketDayHigh": 4.9999, "beta": 1.538, "forwardPE": -1.9691589, "volume": 319662, "regularMarketVolume": 319662, "averageVolume": 160204, "averageVolume10days": 290440, "averageDailyVolume10Day": 290440, "bid": 4.14, "ask": 4.28, "bidSize": 100, "askSize": 500, "marketCap": 212857584, "fiftyTwoWeekLow": 2.44, "fiftyTwoWeekHigh": 8.84, "priceToSalesTrailing12Months": 200.05412, "fiftyDayAverage": 6.2348, "twoHundredDayAverage": 5.3535, "currency": "USD", "enterpriseValue": 102274968, "floatShares": 28626057, "sharesOutstanding": 50512000, "sharesShort": 1914927, "sharesShortPriorMonth": 1684402, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.0381, "heldPercentInsiders": 0.00712, "heldPercentInstitutions": 0.80521005, "shortRatio": 15.58, "shortPercentOfFloat": 0.085, "impliedSharesOutstanding": 50512000, "bookValue": 3.038, "priceToBook": 1.3870968, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -135282000, "trailingEps": -2.51, "forwardEps": -2.14, "enterpriseToRevenue": 96.123, "enterpriseToEbitda": -0.746, "52WeekChange": -0.21303654, "SandP52WeekChange": 0.28043115, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "GLUE", "underlyingSymbol": "GLUE", "shortName": "Monte Rosa Therapeutics, Inc.", "longName": "Monte Rosa Therapeutics, Inc.", "firstTradeDateEpochUtc": 1624541400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e1526429-092c-3bce-8f14-de475e92b666", "messageBoardId": "finmb_690261281", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.214, "targetHighPrice": 20.0, "targetLowPrice": 11.0, "targetMeanPrice": 16.5, "targetMedianPrice": 17.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 192892000, "totalCashPerShare": 3.819, "ebitda": -137031008, "totalDebt": 45182000, "quickRatio": 4.686, "currentRatio": 4.82, "totalRevenue": 1064000, "debtToEquity": 29.624, "revenuePerShare": 0.02, "returnOnAssets": -0.31261998, "returnOnEquity": -0.68281996, "freeCashflow": -53706376, "operatingCashflow": -58561000, "grossMargins": 0.65132004, "operatingMargins": -32.84492, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-21"}]